We cannot rule out a causal relationship as preclinical studies have demonstrated that SSRIs increase prolactin levels [17–19], an accepted risk factor for breast cancer progression [20–22], and facilitate metastasis [23]. This evidence concerns the gene PRL and breast carcinoma.